Free Trial

Avidity Biosciences Q4 2024 Earnings Report

Avidity Biosciences logo
$27.17 -0.93 (-3.32%)
As of 10:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avidity Biosciences EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.76
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Avidity Biosciences Revenue Results

Actual Revenue
$2.97 million
Expected Revenue
$1.74 million
Beat/Miss
Beat by +$1.23 million
YoY Revenue Growth
N/A

Avidity Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Avidity Biosciences Earnings Headlines

Avidity Biosciences completes enrollment in Phase 1/2 Fortitude trial
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA), a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

View Avidity Biosciences Profile

More Earnings Resources from MarketBeat